Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 7, 2022; 28(1): 96-107
Published online Jan 7, 2022. doi: 10.3748/wjg.v28.i1.96
Risk of hepatocellular carcinoma after hepatitis C virus cure
Maria Alejandra Luna-Cuadros, Hao-Wei Chen, Hira Hanif, Mukarram Jamat Ali, Muzammil Muhammad Khan, Daryl Tan-Yeung Lau
Maria Alejandra Luna-Cuadros, Hao-Wei Chen, Hira Hanif, Mukarram Jamat Ali, Muzammil Muhammad Khan, Daryl Tan-Yeung Lau, Liver Center, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States
Author contributions: Luna-Cuadros MA, Chen HW contributed equally to this work; Luna-Cuadros MA, Chen HW organized and wrote significant sections and revision of the manuscript; Hanif H, Khan MM contributed to the literature search and manuscript writing; Ali AJ designed the figures and contributed to the edit and revision of the manuscript; Lau DTY provided guidance on the overall concept and execution of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Daryl Tan-Yeung Lau, MD, MSc, Associate Professor, Liver Center, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 4A, Boston, MA 02215, United States. dlau@bidmc.harvard.edu
Received: May 29, 2021
Peer-review started: May 29, 2021
First decision: June 22, 2021
Revised: July 12, 2021
Accepted: December 25, 2021
Article in press: December 25, 2021
Published online: January 7, 2022
Processing time: 216 Days and 10.7 Hours
Abstract

Hepatitis C virus (HCV) is a significant cause of hepatocellular carcinoma (HCC). The direct-acting antivirals marked a new era of HCV therapy and are associated with greater than 95% cure rate. Successful treatment of chronic hepatitis C greatly reduces the risk of HCC. A proportion of patients, especially those with pre-existing cirrhosis, remain at risk for HCC despite sustained virologic response (SVR). Diabetes mellitus, hepatic steatosis, alcohol consumption and lack of fibrosis regression are associated with risks of HCC after HCV cure. Noninvasive modalities such as aspartate aminotransferase to platelet ratio index and fibrosis-4 index and transient elastography have been used to monitor hepatic fibrosis. More recently, various fibrosis scores have been combined with clinical parameters and other novel biomarkers to predict risks of HCC for patients who achieved SVR. These models still need to be validated and standardized prior to applying to routine clinical care.

Keywords: Hepatitis C virus cure; Hepatocellular carcinoma; Hepatocellular carcinoma risk models; Fibrosis markers; Transient elastography

Core Tip: Direct-acting antivirals (DAA) therapy has revolutionized the treatment for chronic hepatitis C. However, the development of hepatocellular carcinoma (HCC) after achieving DAA-induced sustained virologic response remains a significant concern, especially those with advanced fibrosis. It is critically important to monitor hepatic fibrosis and continue HCC surveillance for patients with pre-existing cirrhosis. Lack of hepatic regression and several comorbid conditions are associated with HCC risks. Some promising models for predicting HCC risks after hepatitis C virus cure are in development.